337 related articles for article (PubMed ID: 10391668)
1. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam.
Albrecht S; Ihmsen H; Hering W; Geisslinger G; Dingemanse J; Schwilden H; Schüttler J
Clin Pharmacol Ther; 1999 Jun; 65(6):630-9. PubMed ID: 10391668
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction.
Platten HP; Schweizer E; Dilger K; Mikus G; Klotz U
Clin Pharmacol Ther; 1998 May; 63(5):552-60. PubMed ID: 9630828
[TBL] [Abstract][Full Text] [Related]
3. Kinetics and EEG effects of midazolam during and after 1-minute, 1-hour, and 3-hour intravenous infusions.
Greenblatt DJ; Ehrenberg BL; Culm KE; Scavone JM; Corbett KE; Friedman HL; Harmatz JS; Shader RI
J Clin Pharmacol; 2004 Jun; 44(6):605-11. PubMed ID: 15145968
[TBL] [Abstract][Full Text] [Related]
4. Mixed-effects modeling of the influence of midazolam on propofol pharmacokinetics.
Vuyk J; Lichtenbelt BJ; Olofsen E; van Kleef JW; Dahan A
Anesth Analg; 2009 May; 108(5):1522-30. PubMed ID: 19372331
[TBL] [Abstract][Full Text] [Related]
5. Intranasal administration of midazolam: pharmacokinetic and pharmacodynamic properties and sedative potential.
Fukuta O; Braham RL; Yanase H; Kurosu K
ASDC J Dent Child; 1997; 64(2):89-98. PubMed ID: 9188997
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam.
Fiset P; Lemmens HL; Egan TD; Shafer SL; Stanski DR
Clin Pharmacol Ther; 1995 Nov; 58(5):567-82. PubMed ID: 7586951
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%.
Knibbe CA; Zuideveld KP; DeJongh J; Kuks PF; Aarts LP; Danhof M
Clin Pharmacol Ther; 2002 Dec; 72(6):670-84. PubMed ID: 12496748
[TBL] [Abstract][Full Text] [Related]
8. Physostigmine reversal of midazolam-induced electroencephalographic changes in healthy subjects.
Ebert U; Oertel R; Kirch W
Clin Pharmacol Ther; 2000 May; 67(5):538-48. PubMed ID: 10824633
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic characterization of the cardiovascular, hypnotic, EEG and ventilatory responses to dexmedetomidine in the rat.
Bol CJJG ; Danhof M; Stanski DR; Mandema JW
J Pharmacol Exp Ther; 1997 Dec; 283(3):1051-8. PubMed ID: 9399976
[TBL] [Abstract][Full Text] [Related]
10. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation.
Wiltshire HR; Kilpatrick GJ; Tilbrook GS; Borkett KM
Anesth Analg; 2012 Aug; 115(2):284-96. PubMed ID: 22253270
[TBL] [Abstract][Full Text] [Related]
11. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam.
Palkama VJ; Ahonen J; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 1999 Jul; 66(1):33-9. PubMed ID: 10430107
[TBL] [Abstract][Full Text] [Related]
12. Propofol reduces the distribution and clearance of midazolam.
Lichtenbelt BJ; Olofsen E; Dahan A; van Kleef JW; Struys MM; Vuyk J
Anesth Analg; 2010 Jun; 110(6):1597-606. PubMed ID: 20435936
[TBL] [Abstract][Full Text] [Related]
13. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics.
Antonik LJ; Goldwater DR; Kilpatrick GJ; Tilbrook GS; Borkett KM
Anesth Analg; 2012 Aug; 115(2):274-83. PubMed ID: 22190555
[TBL] [Abstract][Full Text] [Related]
14. In vivo modeling of the pharmacodynamic interaction between benzodiazepines which differ in intrinsic efficacy.
Mandema JW; Kuck MT; Danhof M
J Pharmacol Exp Ther; 1992 Apr; 261(1):56-61. PubMed ID: 1560385
[TBL] [Abstract][Full Text] [Related]
15. Modelling acute tolerance to the EEG effect of two benzodiazepines.
Ihmsen H; Albrecht S; Hering W; Schüttler J; Schwilden H
Br J Clin Pharmacol; 2004 Feb; 57(2):153-61. PubMed ID: 14748814
[TBL] [Abstract][Full Text] [Related]
16. In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil.
Mandema JW; Tukker E; Danhof M
J Pharmacol Exp Ther; 1992 Jan; 260(1):36-44. PubMed ID: 1309878
[TBL] [Abstract][Full Text] [Related]
17. Clinical sedation scores as indicators of sedative and analgesic drug exposure in intensive care unit patients.
Masica AL; Girard TD; Wilkinson GR; Thomason JW; Truman Pun B; Nair UB; Light RW; Canonico AE; Dunn J; Pandharipande P; Shintani AK; Ely EW
Am J Geriatr Pharmacother; 2007 Sep; 5(3):218-31. PubMed ID: 17996661
[TBL] [Abstract][Full Text] [Related]
18. [Continuous infusion of ketamine and midazolam for prolonged sedation in the intensive care unit].
Kawamata M; Ujike Y; Miyabe M; Kobayashi I; Arakawa J; Namiki A; Imaizumi H; Yamaya K
Masui; 1991 Dec; 40(12):1793-8. PubMed ID: 1770572
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-pharmacodynamic modeling of electroencephalographic effects of midazolam in eight Chinese men.
Lu JF; Chen G; Xiang BR; An DK
Zhongguo Yao Li Xue Bao; 1994 Sep; 15(5):399-403. PubMed ID: 7717060
[TBL] [Abstract][Full Text] [Related]
20. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
